Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-24
2011-05-24
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S315000, C544S336000, C546S184000
Reexamination Certificate
active
07947684
ABSTRACT:
This invention relates to compounds of formulawhich inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.
REFERENCES:
patent: 5364862 (1994-11-01), Spada et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5736554 (1998-04-01), Spada et al.
patent: 6004981 (1999-12-01), Buckman et al.
patent: 6022969 (2000-02-01), Rice et al.
Beil, W., et al., Phenotypic and Functional Characterization of Mast Cells Derived from Renal Tumor Tissues, Experimental Hematology vol. 26, 1998, pp. 158-169.
Bischoff, S C., et al., Quantitative Assessment of Intestinal Eosinophils and Mast Cells in Inflammatory Bowel Disease, Histopathology 1996, vol. 28, pp. 1-13.
Broersma, et al., The Effect Of Thrombin Inhibition In a Rat Arterial Thrombosis Model, Thrombosis Research 64; 405-412, 1991.
Buckley, M., et al., Mast Cell Subpopulations in the Synovial Tissue of Patients with Osteoarthritis: Selective Increase in Numbers of Tryptase-positive, Chymase-negative Mast Cells, Journal of Pathology, vol. 186, 1998, pp. 67-74.
Cairns, et al., Mast Cell Tryptase Stimulates the Synthesis of Type I Collagenin Himan Lung Fibroblasts, J. Clin. Invest., vol. 99, No. 6, Mar. 1997, pp. 1313-1321.
Caughey, G., et al., Substance P and Vasoactive Intestinal Peptide Degradation by Mast Cell Tryptase and Chymase, The Journal of Pharmacology and Experimental Therapeutics, (1988) , vol. 244, No. 1, pp. 133-137.
Franconi, G., et al. et al., Mast Cell Tryptase and Chymase Reverse Airway Smooth Muscle Relaxation Induced by Vasoactive Intestinal Peptide in the Ferret, The Journal of Pharmacology and Experimental Therapeutics, (1989), vol. 248, No. 3, pp. 947-951.
Hasebe, et al., Photochemical generation of aliphatic radicals from benzophenone oxime esters: simple synthesis of alkylbenzenes and alkylpyridines, CAS Abstr. 106:119639-1987:119639, Hasebe et al, Tetr. Lett 27/28,3239-42(1986).
Higuchi, T, et al., Pro-drugs as Novel Drug Delivery Systems, ACS Symposium Series, vol. 14.
Holst, et al., Antithrombotic Effect of Recombinant Truncated Tissue Factor Pathway Inhibitor (TFPI 1-161) in Experimental Venous Thrombosis—A Comparison with Low Molecular Weight Heparin, Thrombosis and Haemostasis, 71 (2) 214-219 (1994).
Irani, et al., Human Conjunctival Mast Cells: Distribution of MCT and MCTC in Vernal Conjunctivitis and Giant Papillary Conjunctivitis, Journal of Allergy and Clinical Immunology, vol. 86, No. 1 pp. 34-40.
Jarvikallio, A, et al., Quantitative Analysis of Tryptase- and Chymase-containing Mast Cells in Atopic Dermatitis and Nummular Eczema, British Journal of Dermatology 1997, vol. 136, pp. 871-877.
Jeziorska, M, et al., Mast Cell Distribution, Activation, and Phenotype in Atherosclerotic Lesions of Human Carotid Arteries, Journal of Pathology, vol. 182, 1997, pp. 115-122.
Komoto, et a., Preparation of .alpha.-[(N-benzoylpiperidinyl) phenoxy] isobutyrates and analogs as hypolipemics, CAS Abstr. 122:81127-1995:58673, Komoto et al, CA 2110095/6/1994.
Kurz, et al., Rat Model Of Arterial Thrombosis Induced by Ferric Chloride, Thrombosis Research 60; 269-280, 1990.
McEuen, et al., Guinea Pig Lung Tryptase, Biochemical Pharmacology, vol. 52, pp. 331-340, 1996.
Naukkarinen, A, et al., Immunohistochemical Analysis of Sensory Nerves and Neuropeptides, and Their Contacts with Mast Cells in Developing and Mature Psoriatic Lesions, Archives of Dermatological Research vol. 285, 1993 pp. 341-346.
Roche, E., et al., Bioreversible Carriers in Drug Design Theory and Application, American Pharmaceutical Association and Pergamon Press, 1987.
Ruoss, Stephen J, et al., Mast Cell Tryptase is a Mitogen for Cultured Fibroblasts, J. Clin. Invest., vol. 88, Aug. 1991, pp. 493-499.
Schwartz, L., et al., The a Form of Human Tryptase Is the Predominant Type Present in Blood at Baseline in Normal Subjects and Is Elevated in Those with Systemic Mastocytosis, The Journal of Clinical Investigation, vol. 96, Dec. 1995, pp. 2702-2710.
Sekizawa, K., et al., Mast Cell Tryptase Causes Airway Smooth Muscle Hyperresponsiveness in Dogs, J. Clin. Invest., vol. 83, Jan. 1989, pp. 175-179.
Steinhoff, M., et al., Agonists of Proteinase-activated Receptor 2 Induce Inflammation by a Neurogenic Mechanism, Nature Medicine, vol. 6, No. 2, Feb. 2000, pp. 151-158.
Tam, et al., Degradation of Airway Neuropeptides by Human Lung Tryptase, Am. J. Respir. Cell Mol. Biol. vol. 3, 1990, pp. 27-32.
Tetlow, L., et al., Distribution, Activation and Tryptase/Chymase Phenotype of Mast Cells in the Rheumatoid Lesion, Annals of the Rheumatic Diseases 1995; vol. 54, pp. 549-555.
Wilson, S J., et al., Inflammatory Mediators in Naturally Occurring Rhinitis, Clinical and Experimental Allergy, 1998, vol. 28, pp. 220-227.
Zhang, M., et al., Mast Cell Tryptase and Asthma, Mediators of Inflammation, vol. 6, 1997, pp. 311-317.
Astles Peter
Eastwood Paul R.
Gong Yong
Levell Julian
Pauls Heinz
Aventis Pharmaceuticals Inc.
Bolcsak James W.
Ward Paul V.
LandOfFree
1-aroyl-piperidinyl benzamidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-aroyl-piperidinyl benzamidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-aroyl-piperidinyl benzamidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2642360